Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- Article
Prosocial Bonuses Increase Employee Satisfaction and Team Performance
By: Lalin Anik, Lara B. Aknin, Elizabeth W. Dunn, Michael I. Norton and Jordi Quoidbach
In three field studies, we explore the impact of providing employees and teammates with prosocial bonuses, a novel type of bonus spent on others rather than on oneself. In Experiment 1, we show that prosocial bonuses in the form of donations to charity lead to happier... View Details
Keywords: Satisfaction; Groups and Teams; Performance; Compensation and Benefits; Philanthropy and Charitable Giving; Banking Industry; Banking Industry; Banking Industry; Canada; Belgium; Australia
Anik, Lalin, Lara B. Aknin, Elizabeth W. Dunn, Michael I. Norton, and Jordi Quoidbach. "Prosocial Bonuses Increase Employee Satisfaction and Team Performance." PLoS ONE 8, no. 9 (September 2013): 1–8.
- 2013
- Working Paper
Prosocial Bonuses Increase Employee Satisfaction and Team Performance
By: Lalin Anik, Lara B. Aknin, Michael I. Norton, Elizabeth W. Dunn and Jordi Quoidbach
In two field studies, we explore the impact of providing employees and teammates with prosocial bonuses, a novel type of bonus spent on others rather than on oneself. In Experiment 1, we show that prosocial bonuses in the form of donations to charity lead to happier... View Details
Keywords: Satisfaction; Groups and Teams; Performance; Compensation and Benefits; Philanthropy and Charitable Giving; Banking Industry; Banking Industry; Banking Industry; Canada; Belgium; Australia
Anik, Lalin, Lara B. Aknin, Michael I. Norton, Elizabeth W. Dunn, and Jordi Quoidbach. "Prosocial Bonuses Increase Employee Satisfaction and Team Performance." Harvard Business School Working Paper, No. 13-095, May 2013.
- October 2023 (Revised April 2024)
- Case
Accounting Red Flags or Red Herrings at Catalent? (A)
By: Joseph Pacelli, ZeSean Ali and Tom Quinn
Fund manager Janet Curie asked for a recommendation about the pharmaceutical company Catalent. The company seemed like a solid investment. However, a pair of research reports issued over the previous two months complicated this narrative. GlassHouse Research, a short... View Details
Keywords: Accounting Audits; Budgets and Budgeting; Earnings Management; Cost Accounting; Fair Value Accounting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Investment; Trust; Business and Shareholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; United States
Pacelli, Joseph, ZeSean Ali, and Tom Quinn. "Accounting Red Flags or Red Herrings at Catalent? (A)." Harvard Business School Case 124-024, October 2023. (Revised April 2024.)
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details
Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Biotechnology Industry; Biotechnology Industry
Crane, Dwight B., Paul W. Marshall, and Indra Reinbergs. "Kendle International Inc." Harvard Business School Case 200-033, February 2000. (Revised October 2000.)
- May 2007 (Revised September 2008)
- Case
Biocon Limited
By: Krishna G. Palepu and Ananth Chepuri
Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details
Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India
Palepu, Krishna G., and Ananth Chepuri. "Biocon Limited." Harvard Business School Case 107-083, May 2007. (Revised September 2008.)
- 3 Jun 2023
- Talk
Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
Keywords: Policy; Health Pandemics; Health Care and Treatment; Innovation and Invention; Health Industry; Health Industry
Herzlinger, Regina E. "Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen." Harvard Business School Alumni Reunion, Boston, MA, June 3, 2023. (Link to cases described in this talk.)
Henry W. McGee
Henry McGee joined the HBS faculty in 2013 after retiring as President of HBO Home Entertainment, the digital and DVD program distribution division of Home Box Office, the pioneering premium television company. A member of the Entrepreneurial Management Unit,... View Details
- July 2016
- Case
Product Portfolio Management at Genentech
By: Kevin Schulman and Jamie Gresh
Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details
Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Biotechnology Industry; Biotechnology Industry; United States
Schulman, Kevin, and Jamie Gresh. "Product Portfolio Management at Genentech." Harvard Business School Case 317-012, July 2016.
- September 2007 (Revised December 2008)
- Case
Michael Fernandes at Nicholas Piramal
By: Michel Anteby and Nitin Nohria
Michael Fernandes, the Director of Custom Manufacturing Operations at the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedules a meeting with three of his reports, whose interpersonal conflicts with one another are causing his business development... View Details
Keywords: Interpersonal Communication; Management Skills; Groups and Teams; Conflict Management; Cooperation; Pharmaceutical Industry; India; United Kingdom; Canada
Anteby, Michel, and Nitin Nohria. "Michael Fernandes at Nicholas Piramal." Harvard Business School Case 408-001, September 2007. (Revised December 2008.)
Michael Beer
MICHAEL BEER
Mike Beer is the Cahners-Rabb Professor of Business Administration, Emeritus at the Harvard Business School and author Fit to Compete: Why Honest Conversations About Your Company’s... View Details
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry
Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
- 03 Apr 2007
- First Look
First Look: April 3, 2007
another EMR company offered eCW the chance to grow quickly in an industry that is estimated to take in more than $40 billion in overall revenues in 2007. But this acquisition would require outside financing of some sort. Was this the... View Details
Keywords: Martha Lagace
- September 2023 (Revised December 2023)
- Case
TetraScience: Noise and Signal
By: Thomas R. Eisenmann and Tom Quinn
In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details
Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Biotechnology Industry; Biotechnology Industry; United States; Boston
Eisenmann, Thomas R., and Tom Quinn. "TetraScience: Noise and Signal." Harvard Business School Case 824-024, September 2023. (Revised December 2023.)
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- February 1996 (Revised April 2004)
- Case
Eli Lilly and Company: Innovation in Diabetes Care
By: Clayton M. Christensen
Summarizes Eli Lilly's history of innovation in its business, describing how the dimensions along which innovations have been made in the industry have changed. Lilly's innovation strategy has been to pursue ever higher performance products, while others in the... View Details
Keywords: Change; Product; Service Delivery; Product Development; Innovation and Management; Innovation Strategy; Health Care and Treatment; Pharmaceutical Industry
Christensen, Clayton M. "Eli Lilly and Company: Innovation in Diabetes Care." Harvard Business School Case 696-077, February 1996. (Revised April 2004.)
- December 1997
- Case
American Cyanamid (A) & (B) (Combined)
American Home Products' (AHP) $9 billion hostile takeover of American Cyanamid (Cyanamid) was the largest merger-and-acquistion transaction in 1994, and made AHP the fourth largest pharmaceutical firm in the United States. At the time of AHP's offer, Cyanamid had... View Details
Keywords: Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Conflict and Resolution; Pharmaceutical Industry
Wruck, Karen, and Sherry P. Roper. "American Cyanamid (A) & (B) (Combined)." Harvard Business School Case 898-120, December 1997.
V. Kasturi Rangan
Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
Keywords: Business or Company Management; Technological Innovation; Innovation and Management; Growth and Development Strategy; Problems and Challenges; Production; Research and Development; Organizational Change and Adaptation; Pharmaceutical Industry; Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)